{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:32:47Z","timestamp":1773657167574,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1067\/mhj.2002.129970","type":"journal-article","created":{"date-parts":[[2002,12,27]],"date-time":"2002-12-27T17:26:00Z","timestamp":1041009960000},"page":"S12-S18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"S","title":["Clinical implications of aldosterone blockade"],"prefix":"10.1067","volume":"144","author":[{"given":"Michael A.","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1067\/mhj.2002.129970_bib1","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.129970_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11906-000-0017-z","article-title":"Aldosterone and vascular damage","volume":"2","author":"Duprez","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"10.1067\/mhj.2002.129970_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0002-9149(93)90239-9","article-title":"Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension","volume":"71","author":"Brilla","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1067\/mhj.2002.129970_bib4","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1067\/mhj.2002.129970_bib5","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1067\/mhj.2002.129970_bib6","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0735-1097(01)01243-8","article-title":"Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure","volume":"37","author":"Yee","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.129970_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.129970_bib8","first-page":"521","article-title":"Eplerenone (GD Searle & Co)","volume":"2","author":"Martin","year":"2001","journal-title":"Current Opin Invest Drugs"},{"key":"10.1067\/mhj.2002.129970_bib9","first-page":"488","article-title":"Eplerenone: antihypertensive, treatment of heart failure, aldosterone antagonist","volume":"24","author":"Rabasseda","year":"1999","journal-title":"Drugs Future"},{"key":"10.1067\/mhj.2002.129970_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1471-4892(01)00022-4","article-title":"Recent studies with eplerenone, a novel selective aldosterone receptor antagonist","volume":"1","author":"McMahon","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1067\/mhj.2002.129970_bib11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.1996.03530440051036","article-title":"Blood pressure as a cardiovascular risk factor: prevention and treatment","volume":"275","author":"Kannel","year":"1996","journal-title":"JAMA"},{"key":"10.1067\/mhj.2002.129970_bib12","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1161\/01.HYP.37.5.1256","article-title":"Cardiovascular mortality in hypertensive men according to presence of associated risk factors","volume":"37","author":"Thomas","year":"2001","journal-title":"Hypertension"},{"key":"10.1067\/mhj.2002.129970_bib13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0895-7061(01)02211-7","article-title":"Distribution of blood pressure and hypertension in Canada and the United States","volume":"14","author":"Joffres","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1067\/mhj.2002.129970_bib14","series-title":"The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: 98-4080","author":"JNC VI","year":"1997"},{"key":"10.1067\/mhj.2002.129970_bib15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/hyp.38.4.827","article-title":"Improved hypertension management and control: results from the Health Survey for England 1998","volume":"38","author":"Primatesta","year":"2001","journal-title":"Hypertension"},{"key":"10.1067\/mhj.2002.129970_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/01.HYP.38.3.449","article-title":"Prevalence and therapeutic control of hypertension in 30,000 subjects in the workplace","volume":"38","author":"Lang","year":"2001","journal-title":"Hypertension"},{"key":"10.1067\/mhj.2002.129970_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/01.HYP.25.3.305","article-title":"Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991","volume":"25","author":"Burt","year":"1995","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"10.1067\/mhj.2002.129970_bib18","first-page":"S33","article-title":"Standards of medical care for patients with diabetes mellitus","volume":"24","author":"American Diabetes Association","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1067\/mhj.2002.129970_bib19","doi-asserted-by":"crossref","first-page":"310S","DOI":"10.1016\/S0895-7061(01)02237-3","article-title":"Antihypertensive treatment of patients with diabetes and hypertension","volume":"14","author":"Julius","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1067\/mhj.2002.129970_bib20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"issue":"2 Suppl 1","key":"10.1067\/mhj.2002.129970_bib21","first-page":"S40","volume":"34","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1067\/mhj.2002.129970_bib22","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.129970_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1067\/mhj.2002.129970_bib24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1067\/mhj.2002.129970_bib25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-convertingBenzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.129970_bib26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.129970_bib27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.129970_bib28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men\u2014a comparison of six antihypertensive agents with placebo","volume":"328","author":"Materson","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.129970_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/01.HYP.30.3.428","article-title":"Effects of blood pressure control on progressive renal disease in blacks and whites","volume":"30","author":"Hebert","year":"1997","journal-title":"Hypertension"},{"key":"10.1067\/mhj.2002.129970_bib30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0895-7061(00)00280-6","article-title":"Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study","volume":"13","author":"Kjeldsen","year":"2000","journal-title":"Am J Hypertens"},{"key":"10.1067\/mhj.2002.129970_bib31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension","volume":"338","author":"Estacio","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.129970_bib32","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study: a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.129970_bib33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1067\/mhj.2002.129970_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870302002120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870302002120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T04:49:14Z","timestamp":1757566154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870302002120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["S0002870302002120"],"URL":"https:\/\/doi.org\/10.1067\/mhj.2002.129970","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of aldosterone blockade","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1067\/mhj.2002.129970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}